Altropane Dose for Imaging Patients With Suspected Parkinson's Disease
An Open-label Multicenter Phase 2 Dose-evaluation Study of Altropane (123I) Injection for Striatal Dopamine Transporter Visualization Using SPECT Brain Imaging
Sponsor: Fortrea
Terminated
Business Decision
Listed as NCT05636852, this PHASE2 trial focuses on Movement Disorders and Parkinson Disease and remains terminated or withdrawn. Sponsored by Fortrea, it has been updated 13 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Aug 2025 — Present [monthly]
Terminated PHASE2
-
Dec 2024 — Aug 2025 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Oct 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 8 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Mar 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2023 — Mar 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fortrea
- GE Healthcare
For direct contact, visit the study record on ClinicalTrials.gov .